We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

179 hedge funds and large institutions have $826M invested in Acorda Therapeutics in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 55 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

154% more call options, than puts

Call options by funds: $38.5M | Put options by funds: $15.2M

37% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 19

16% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 55

3% more funds holding

Funds holding: 174 → 179 (+5)

19% less capital invested

Capital invested by funds: $1.01B → $826M (-$189M)

Holders
179
Holders Change
+5
Holders Change %
+2.87%
% of All Funds
3.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
64
Reduced
55
Closed
19
Calls
$38.5M
Puts
$15.2M
Net Calls
+$23.3M
Net Calls Change
-$2.58M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$16.5M
2
BlackRock
BlackRock
New York
+$15.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
4
Marshall Wace
Marshall Wace
United Kingdom
+$7.23M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$5.58M

Top Sellers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
-$29.3M
2
Bank of America
Bank of America
North Carolina
-$7.81M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.62M
4
Deutsche Bank
Deutsche Bank
Germany
-$4.82M
5
First Trust Advisors
First Trust Advisors
Illinois
-$3.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.97M -$118K -54 -2%
Ameriprise
27
Ameriprise
Minnesota
$4.56M +$155K +71 +3%
Citadel Advisors
28
Citadel Advisors
Florida
$4.14M +$4.81M +2,212 New
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$3.89M -$2.62M -1,203 -37%
JP Morgan Chase
30
JP Morgan Chase
New York
$3.84M -$111K -51 -2%
Bank of America
31
Bank of America
North Carolina
$3.5M -$7.81M -3,587 -66%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$3.46M -$770K -354 -16%
Connor, Clark & Lunn Investment Management (CC&L)
33
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.38M +$1.72M +792 +78%
BCM
34
Bridgeway Capital Management
Texas
$3.38M +$3.93M +1,808 New
TCIM
35
TIAA CREF Investment Management
New York
$3.23M -$265K -122 -7%
Citigroup
36
Citigroup
New York
$3.05M +$3.04M +1,397 +600%
AQR Capital Management
37
AQR Capital Management
Connecticut
$2.59M +$814K +374 +37%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$2.55M +$773K +355 +35%
American Century Companies
39
American Century Companies
Missouri
$2.55M +$361K +166 +14%
Two Sigma Investments
40
Two Sigma Investments
New York
$2.51M +$2.92M +1,342 New
UBS Group
41
UBS Group
Switzerland
$2.45M +$2.33M +1,069 +442%
TA
42
Teachers Advisors
New York
$2.45M – – –
MCM
43
Matarin Capital Management
New York
$2.12M -$376K -173 -13%
Man Group
44
Man Group
United Kingdom
$2.09M +$825K +379 +51%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$1.95M +$394K +181 +21%
PPA
46
Parametric Portfolio Associates
Washington
$1.86M -$242K -111 -10%
Robeco Institutional Asset Management
47
Robeco Institutional Asset Management
Netherlands
$1.76M +$2.07M +953 New
Squarepoint
48
Squarepoint
New York
$1.73M -$276K -127 -12%
AA
49
ALPS Advisors
Colorado
$1.71M +$470K +216 +31%
Russell Investments Group
50
Russell Investments Group
United Kingdom
$1.62M +$981K +451 +105%
1
2
3 4 5

ACOR Hedge Fund Activity: Q4 2018 in Review

179 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2018, worth a combined $826M — down 19% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ACOR positions and 19 closed out — a net gain of 7 holders — while 64 added to existing stakes and 55 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $16.5M. The largest seller was Scopia Capital Management, cutting an estimated $29.3M.

  • 179 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2018, up from 174 in Q3 2018.
  • Funds reported $826M of Acorda Therapeutics stock for Q4 2018, down 19% quarter-over-quarter.
  • 26 funds opened new Acorda Therapeutics positions in Q4 2018 and 19 closed out, a net change of +7 holders.
  • The largest Acorda Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $16.5M added.
  • The largest Acorda Therapeutics seller in Q4 2018 was Scopia Capital Management, an estimated $29.3M sold.

Based on aggregated 13F filings for Q4 2018.